INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
Portfolio Pulse from
INmune Bio Inc. has completed the Phase I portion of its INKmune™ trial for metastatic castration-resistant prostate cancer and is now opening the Phase II high dose cohort.
February 12, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio Inc. has successfully completed the highest dose cohort in Phase I of its INKmune™ trial for prostate cancer, progressing to Phase II. This advancement could positively impact INMB's stock as it demonstrates progress in their NK cell therapy development.
The completion of the highest dose cohort in Phase I and the transition to Phase II in the INKmune™ trial is a significant milestone for INmune Bio. This progress in their NK cell therapy could enhance investor confidence and positively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100